NO20080259L - Interaksjoner av Moraxella catarrhalis med epitelceller, ekstracellulaere matriksproteiner og komplementsystemet - Google Patents

Interaksjoner av Moraxella catarrhalis med epitelceller, ekstracellulaere matriksproteiner og komplementsystemet

Info

Publication number
NO20080259L
NO20080259L NO20080259A NO20080259A NO20080259L NO 20080259 L NO20080259 L NO 20080259L NO 20080259 A NO20080259 A NO 20080259A NO 20080259 A NO20080259 A NO 20080259A NO 20080259 L NO20080259 L NO 20080259L
Authority
NO
Norway
Prior art keywords
complement system
epithelial cells
extracellular matrix
interactions
moraxella catarrhalis
Prior art date
Application number
NO20080259A
Other languages
English (en)
Norwegian (no)
Inventor
Arne Forsgren
Kristian Riesbeck
Original Assignee
Arne Forsgren Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arne Forsgren Ab filed Critical Arne Forsgren Ab
Publication of NO20080259L publication Critical patent/NO20080259L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
NO20080259A 2005-08-10 2008-01-14 Interaksjoner av Moraxella catarrhalis med epitelceller, ekstracellulaere matriksproteiner og komplementsystemet NO20080259L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70674505P 2005-08-10 2005-08-10
US70714805P 2005-08-11 2005-08-11
PCT/SE2006/000931 WO2007018463A2 (fr) 2005-08-10 2006-08-08 Interaction de moraxella catarrhalis avec des cellules epitheliales, des proteines matricielles extracellulaires et le systeme complementaire

Publications (1)

Publication Number Publication Date
NO20080259L true NO20080259L (no) 2008-05-13

Family

ID=37727738

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080259A NO20080259L (no) 2005-08-10 2008-01-14 Interaksjoner av Moraxella catarrhalis med epitelceller, ekstracellulaere matriksproteiner og komplementsystemet

Country Status (15)

Country Link
US (7) US8092811B2 (fr)
EP (4) EP1913019B1 (fr)
JP (2) JP5269594B2 (fr)
KR (1) KR20080042865A (fr)
AU (1) AU2006277076B2 (fr)
BR (1) BRPI0614734A2 (fr)
CA (1) CA2618554C (fr)
EA (1) EA014352B1 (fr)
ES (1) ES2537274T3 (fr)
IL (2) IL189258A0 (fr)
MA (1) MA29765B1 (fr)
MX (1) MX2008002037A (fr)
NO (1) NO20080259L (fr)
NZ (1) NZ565651A (fr)
WO (1) WO2007018463A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092811B2 (en) * 2005-08-10 2012-01-10 Arne Forsgren Ab Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
SG194886A1 (en) * 2011-05-11 2013-12-30 Riesbeck Healthcare Sweden Ab Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2018178265A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et procédé de traitement
US11167022B2 (en) 2017-03-31 2021-11-09 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US11723966B2 (en) 2017-08-14 2023-08-15 Glaxosmithkline Biologicals Sa Methods of boosting immune responses
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
BR112021026565A2 (pt) 2019-08-05 2022-05-03 Glaxosmithkline Biologicals Sa Composição imunogênica
BR112021026775A2 (pt) 2019-08-05 2022-05-10 Glaxosmithkline Biologicals Sa Processo para preparar uma composição que compreende um polipeptídeo de proteína d
US20230266317A1 (en) 2019-09-11 2023-08-24 Glaxosmithkline Biologicals Sa Antigen binding protein and assays
JP2024510717A (ja) 2021-02-22 2024-03-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物、使用及び方法
CN114409756B (zh) * 2022-01-21 2023-06-09 中国科学院海洋研究所 一种牙鲆补体成分C3（PoC3）的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454403B (sv) 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US5843463A (en) 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
BR9714160A (pt) * 1996-12-20 2000-05-02 Univ Texas Antìgenos uspa1 e uspa2 de moraxella catarrhalis
GB0003502D0 (en) 2000-02-15 2000-04-05 Smithkline Beecham Sa Vaccine
PT2088197T (pt) 2000-10-02 2016-08-01 Id Biomedical Corp Quebec Antigénios de haemophilus influenzae e fragmentos de adn correspondentes
SE0102410D0 (sv) 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
RU2323002C2 (ru) * 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
GB0222764D0 (en) * 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
US8092811B2 (en) * 2005-08-10 2012-01-10 Arne Forsgren Ab Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
ZA200805602B (en) 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)

Also Published As

Publication number Publication date
EP2548885A2 (fr) 2013-01-23
BRPI0614734A2 (pt) 2011-04-12
EA014352B1 (ru) 2010-10-29
ES2537274T3 (es) 2015-06-05
MA29765B1 (fr) 2008-09-01
EP2548884A3 (fr) 2013-05-01
US20100062027A1 (en) 2010-03-11
JP5763113B2 (ja) 2015-08-12
US8323667B2 (en) 2012-12-04
MX2008002037A (es) 2008-03-27
EP2548885B1 (fr) 2017-10-18
AU2006277076B2 (en) 2012-03-29
US8092811B2 (en) 2012-01-10
US10786562B2 (en) 2020-09-29
US20170281746A1 (en) 2017-10-05
US20160318979A1 (en) 2016-11-03
US9255127B2 (en) 2016-02-09
EP2548884B1 (fr) 2017-08-02
WO2007018463A3 (fr) 2007-05-10
EP2548885A3 (fr) 2013-05-01
AU2006277076A1 (en) 2007-02-15
US20190117757A1 (en) 2019-04-25
NZ565651A (en) 2012-01-12
WO2007018463A2 (fr) 2007-02-15
EP2548884A2 (fr) 2013-01-23
IL216703A0 (en) 2012-01-31
CA2618554C (fr) 2017-03-07
US20120148614A1 (en) 2012-06-14
KR20080042865A (ko) 2008-05-15
EP1913019A2 (fr) 2008-04-23
EA200800565A1 (ru) 2008-10-30
US20130129763A1 (en) 2013-05-23
JP2013150614A (ja) 2013-08-08
EP3305807A1 (fr) 2018-04-11
JP2009504152A (ja) 2009-02-05
EP1913019B1 (fr) 2014-12-31
JP5269594B2 (ja) 2013-08-21
CA2618554A1 (fr) 2007-02-15
US9657067B2 (en) 2017-05-23
US20150140026A1 (en) 2015-05-21
US10183071B2 (en) 2019-01-22
IL189258A0 (en) 2008-08-07
US8895030B2 (en) 2014-11-25

Similar Documents

Publication Publication Date Title
NO20080259L (no) Interaksjoner av Moraxella catarrhalis med epitelceller, ekstracellulaere matriksproteiner og komplementsystemet
AU2019268194A1 (en) Cell culture system
JOP20190017B1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
NZ584893A (en) PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
WO2008147816A3 (fr) Compositions et procédés d'affichage de protéines sur la surface de bactéries et leurs vésicules dérivées et utilisations de celles-ci
NO20083266L (no) Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser
NO20082716L (no) Sammensetninger og fremgangsmater for fremstilling av en sammensetning
CY1110734T1 (el) Μεθοδος παραγωγης μονιμων ανθρωπινων κυτταρικων σειρων
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
WO2006073748A3 (fr) Methode de traitement de maladies auto-immunes par induction de la presentation d'antigene par des cellules presentatrices d'antigene induisant une tolerance
WO2007098415A3 (fr) Inhibition à base de péptide d'une interaction de capcna dans un cancer
DK1846974T3 (da) Membran-elektrode samlinger til brændstofceller, deres fremstilling og anvendelse og brændstofceller indeholdende disse
WO2005094353A3 (fr) Techniques de production de lymphocytes t regulateurs et utilisation de ceux-ci
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
BRPI0620648A8 (pt) variação de um domínio d3 da interleucina-12p40, proteína il-12 ou um fragmento da mesma, proteína de fusão, ácido nucléico, vetor de expressão, célula hospedeira, composição farmacêutica e uso da mesma
WO2007130642A3 (fr) Modulation du nkg2d
EP2145953A4 (fr) Systeme acellulaire de synthese de proteines issues de cellules mammiferes mises en culture
WO2008085962A3 (fr) Méthodes de culture cellulaire destinées à la production de protéines recombinées en présence de niveaux réduits d'un ou plusieurs contaminants
NO20076391L (no) Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin
DK1987357T3 (da) Polypeptider, som genkendes af anti-Trichinella-antistoffer, og anvendelser deraf
AR057058A1 (es) Metodo para usar antagonistas de zonulina para prevenir la perdida o para regenerar celulas pancreaticas
BR122018077204B8 (pt) peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica
WO2018120843A9 (fr) Molécule trifonctionnelle et son application
NZ603942A (en) Vitronectin:keratinocyte growth factor chimeras

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application